← All trials
NCT06152991
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 25, 2023
- Primary completion
- Jun 30, 2026
- Completion date
- Feb 26, 2027
- First posted
- Dec 1, 2023
- Last posted
- Dec 1, 2023
- Enrollment
- 196
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Seoul National UniversityLead sponsor
- Seoul National UniversityOverall official - principal investigator
- Seoul National UniversitySponsor investigator
- Seoul National UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.